In an analysis conducted in 2023 of unselected BC testing, it was estimated that among women presenting with BC, fewer than 20% were eligible for testing via the NTD criteria, missing approximately half of those identified to have gPVs in high-penetrance BRCA genes (BRCA1, BRCA2 and PALB2).4 This evidence concerns the gene PALB2 and breast cancer.